A new publication from Celon Pharma S.A. laboratories!

Our new publication on experimental oncology has just appeared! The article entitled "Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma." by Daria Zdzalik and co-workers was published in Journal of Cancer Research and Clinical Oncology and is freely available via PubMed/PMC.